<DOC>
	<DOCNO>NCT01150201</DOCNO>
	<brief_summary>Study objective : To investigate potential anti-proteinuric renoprotective efficacy aliskiren addition losartan patient risk develop end-stage renal disease ( ESRD ) Methods : This randomize , double-blind study proteinuric , non-diabetic patient chronic kidney disease ( CKD ) assign 1:1 ratio one follow treatment group 3 year : - Group A : Losartan ( Control arm : conventional treatment ) * - Group B : Aliskiren plus Losartan ( Intervention arm ) * - With optional addition anti-hypertensive agent achieve optimal target blood pressure &lt; 130/80 mmHg .</brief_summary>
	<brief_title>Aliskiren Combined With Losartan Proteinuric , Non-diabetic Chronic Kidney Disease</brief_title>
	<detailed_description>Aliskiren direct renin inhibitor show reduce proteinuria retard renal deterioration type 2 diabetic patient overt nephropathy . However , know therapeutic effect extend nondiabetic chronic renal disease . The current study aim explore research question randomly assign patient various stage chronic renal disease receive either aliskiren top losartan , continuation losartan .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Male female 18 80 year age Presence nondiabetic CKD stag 3 4 define estimate glomerular filtration rate ( eGFR 4variable MDRD equation ) follow : Stage 3 : Moderate decrease GFR 3059 mL/min/1.73 sq.m Stage 4 : Severe decrease GFR 1529 mL/min/1.73 sq.m CKD define either kidney damage GFR &lt; 60 mL/min/1.73 m2 &gt; 3 month variation le 30 % 3 month screen Earlymorning urinary proteintocreatinine ratio &gt; 500 mg/g 57 mg/mmol least 2 occasion four week apart Patients willing give write , informed consent eGFR &lt; 15 &gt; 60 ml/min/1.73m2 Earlymorning urinary proteintocreatinine ratio &gt; 5000 mg/g 570 mg/mmol , urinary proteintocreatinine ratio &lt; 500 mg/g 57 mg/mmol Serum K+ &gt; 5.2 mmol/L Presence bilateral renal artery stenosis Known allergy losartan aliskiren Patients receive angiotensin II receptor blocker / angiotensin convert enzyme inhibitor combination within 12 week randomization Concurrent treatment corticosteroid , nonsteroidal antiinflammatory drug , immunosuppressive agent Patients connective tissue disease obstructive uropathy Patients concomitant malignancy condition severely limit life expectancy Female pregnant intend conceive Female childbearing age unwilling practice effective contraception Patients unable give inform consent Patients simultaneously participate another study participate another study within last 30 day entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>CKD</keyword>
	<keyword>proteinuria</keyword>
	<keyword>eGFR</keyword>
	<keyword>Progression chronic kidney disease</keyword>
</DOC>